Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88
Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
Express News | Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88
